Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Published:2014-05-08 Issue:19 Volume:123 Page:2960-2967
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Middeke Jan M.¹,Fang Min²,Cornelissen Jan J.³,Mohr Brigitte¹,Appelbaum Frederick R.²,Stadler Michael⁴,Sanz Jaime⁵,Baurmann Herrad⁶,Bug Gesine⁷,Schäfer-Eckart Kerstin⁸,Hegenbart Ute⁹,Bochtler Tilmann⁹,Röllig Christoph¹,Stölzel Friedrich¹,Walter Roland B.²,Ehninger Gerhard¹,Bornhäuser Martin¹,Löwenberg Bob³,Schetelig Johannes¹¹⁰

Affiliation:

1. Universitätsklinikum Carl Gustav Carus der Technische Universität Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany;

2. Fred Hutchinson Cancer Research Center, Seattle, WA;

3. Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;

4. Medizinische Hochschule Hannover, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Hannover, Germany;

5. Department of Hematology, Hospital Universitario La Fe, Valencia University Medical School, Valencia, Spain;

6. Stiftung Deutsche Klinik für Diagnostik GmbH, Zentrum für Blutstammzell- und Knochenmarktransplantation, Wiesbaden, Germany;

7. Klinikum der Johann Wolfgang Goethe Universität Frankfurt am Main, Medizinische Klinik II, Frankfurt, Germany;

8. Städtisches Klinikum Nord, 5. Medizinische Klinik, Nürnberg, Germany;

9. Universität Heidelberg, Medizinische Klinik und Poliklinik, Abteilung Innere Medizin V, Heidelberg, Germany; and

10. Deutsche Knochenmarkspenderdatei (German Bone Marrow Donor Center), Clinical Trials Unit, Dresden, Germany

Abstract

Key Points Patients with abnl(17p) AML have a poor outcome after allogeneic hematopoietic stem cell transplantation.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/19/2960/1376262/2960.pdf

Reference28 articles.

1. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.;Döhner;Blood,2010

2. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.;Slovak;Blood,2000

3. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.;Suciu;Blood,2003

4. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?;Cornelissen;Blood,2007

5. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.;Schlenk;J Clin Oncol,2010

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologic and Clinical Characteristics of Isochromosome der(17)(q10)t(15;17) in Acute Promyelocytic Leukemia;Acta Haematologica;2024-05-31

2. The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy;Frontiers in Immunology;2024-03-15

3. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML;Blood Advances;2024-02-13

4. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML;Leukemia;2023-11-07

5. A novel mesenchymal stem cell-based regimen for acute myeloid leukemia differentiation therapy;Acta Pharmaceutica Sinica B;2023-07